APACC
Meeting category
Date(s)
1 Jun 2017 - 3 Jun 2017
Location
Hong Kong, Hong Kong
Organizer
Titanium Level Support
Sponsor logos
ViiW
gilead

APACC 2017

Related Enduring Materials

Enduring Materials
Plenairy session 1: Opening session -
Key note lecture: HIV/AIDS in the Asia Pacific: Where is the Epidemic Heading?
Beyrer
Chris Beyrer
John Hopkins University, Center for AIDS Research, USA
Program implementer perspective
Fujie Zhang, MD, PhD
Beijing Ditan Hospital, Capital Medical University, China
Community Perspective
Parallel session 1: Emerging ART management paradigms - Are 2 drugs enough? -
ART: are two drugs enough?
The SWORD study
Chien-Ching Hung, MD, PhD
National Taiwan University Hospital & National Taiwan University Hospital Yunlin Branch / National Taiwan University College of Medicine, Taiwan
Abstract presentations
Treatment-emerged adverse events and health-related quality of life in HIV-infected patients after stable switch from boosted protease inhibitors to Raltegravir: A multicenter, cohort study
Dr. S.S.J. Lee
Kaohsiung Veterans General Hospital, Taiwan
Efficacy and safety of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide (E/C/F/TAF) in virologically suppressed asian adults with renal impairment
Dr. B. Chin
National Medical Center/Center for Infectious Diseases, South Korea
Parallel session 2: Opportunistic Infections -
What’s new in the management of fungal opportunistic infections (not available)rmission for publication))
Thuy Le, MD, DPhil
Duke University; Oxford University Clinical Research Unit, United States / Vietnam
Identifying TB co-infection - new approaches
 Chuchottaworn
Charoen Chuchottaworn
Central Chest in Nonthaburi, Thailand
Abstract presentations
Cost effectiveness of a screening program for Cryptococcal antigenemia among antiretroviral naive HIV infected patients with CD4< 100 cell/cumm in a referral HIV care center at MCross Anonymous Clinic in Bangkok, Thailand: A five-year observational cohort
Dr. S. Rama
Asha Kirana Hospital, India
Acute Shigellosis among HIV-infected people in 2015: An outbreak investigation
Dr. Y.T. Shen
Centers for Disease Control, Taiwan
HIV care in Yangon, Myanmar; successes, challenges and implications for policy
Dr. J. Hanson
The Kirby Institute, University of New South Wales, Australia
Parallel session 3: Point of Care testing -
Innovative ways to stimulate the demand of HIV and HCV testing
Philip Cunningham
Philip Cunningham
The Kirby Institute, University of New South Wales, Australia
Abstract presentations
The clinical utility of the urine based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: a prospective, hospital-based study
Dr. J. Hanson
The Kirby Institute, University of New South Wales, Australia
HIV prevalence in men who have sex with men in Shinjuku 2-chome gay town, Tokyo: Result from the HIV testing program using the home collection kit
Dr. M. Takano
National Center for Global Health and Medicine, Japan
HIV testing as the bridge between awareness and acceptance of PrEP among MSM
Dr. T.H. Kwan
Jockey Club School of Public Health and Primary Care, Hong Kong
Plenairy session 2: Challenges in Long-term HIV care -
Mental health and neurocognitive issues related to adolescents who have grown up with HIV
Warren Y.K. NG
Warren Y.K. NG
Columbia University Medical Center, USA
Aging among adults in the context of HIV
Reena Rajasuriar, MPharm, PhD
University of Malaya, Malaysia
Neurocognitive issues among aging adults
Edwina Wright
Edwina Wright
Alfred Health & Burnet Institute, Australia
Parallel session 4: Treatment Failure & Resistance -
Does resistance still matter?
Daniel Kuritzkes, MD
Brigham and Women's Hospital / Harvard Medical School, United States
Resistance testing for selecting second line drugs
Nicholas Paton, MD, FRCP
National University of Singapore, Singapore
Clinical Case presentation
Chien-Ching Hung, MD, PhD
National Taiwan University Hospital & National Taiwan University Hospital Yunlin Branch / National Taiwan University College of Medicine, Taiwan
Abstract presentations
The emergence of transmitted protease inhibitor resistance mutations in adults starting antiretroviral therapy in northern Vietnam
Dr. T. Le
Oxford University Clinical Research Unit, the Hospital for Tropical Diseases, Vietnam
Highly automated deep sequencing-based HIV-1 drug resistance monitoring system
Dr. E. Rakhmanaliev
Vela Diagnostics, Singapore
Parallel session 5: Hepatitis HIV Co-infection -
Outbreak of hepatitis A among HIV-infected men who have sex with men in Hong Kong (not available)
placeholder3
Dr. C.K.B. Wong
Special Preventive Programme, Centre for Health Protection, Department of Health, Hong Kong
HIV and intestinal co-infections
 Ivan Hung
Ivan Hung
The University of Hong Kong, Hong Kong
Abstract presentations
High-risk behaviour in a cohort of HIV/hepatitis C coinfected gay and bisexual men commencing hepatitis C treatment (not available)
Dr. J. Dole
Burnet Institute, Australia
Suitability of HCV treatment in primary care settings for individuals with HIV/hepatitis C coinfection (not available)
Dr. J. Dole
Burnet Institute, Australia
Treatment of patients with chronic hepatitis C genotype 3 infection with or without cirrhosis with sofosbuvir and daclatasvir therapy
Dr. O. Goyal
Dayanand Medical College and Hospital, Country
Drug interactions between anti-HCV Antivirals Ledipasvir/Sofosbuvir and integrase strand transfer inhibitor-based regimens
Dr. D. Mccoll
Gilead Sciences Inc., Singapore
Parallel session 7: Key populations -
HIV and adolescents: How do we help them to prepare for adult lifeation?
Rangsima Lolekha
Rangsima Lolekha
Thailand Ministry of Public Health-U.S. CDC Collaboration, Thailand
Abstract presentations
Transition into adult care: Factors associated with level of preparedness among adolescents living with HIV in Cambodia
Dr. S. Yi
Khana Center for Population Health Research, Cambodia
Increase new case detection of HIV among MSM and TG through PDI+
Dr. K. So
Khmer HIV/AIDS NGO Alliance (KHANA), Cambodia
Factors associated with HIV infection among transgender women in Cambodia: Results from a national integrated biological and behavioral survey
Dr. S. Yi
Khana Center for Population Health Research, Cambodi
Gender difference in compliance with self-deferral for blood donation on HIV-related risk (not available)
Dr. K.H. Cheung
Stanley Ho Centre for Emerging Infectious Diseases, Hong Kong
Parallel session 8: Comorbidities (non-AIDS related) -
Renal disease and HIV
Sanjay Pujari
Sanjay Pujari
Institute of Infectious Diseases, India
Cardiovascular disease and HIV
Sungkanuparph
Somnuek Sungkanuparph
Ramathibodi Hospital, Mahidol University, Thailand
Abstract presentations
Assessment of atherosclerotic cardiovascular disease (ASCVD) risks between HIV-infected patients receiving first-line and second-line antiretroviral therapy
Dr. J. Tiarukkitsagul
Ramathibodi Hospital, Mahidol University, Thailand
Higher burden of chronic comorbidities among aged hospitalized HIV patients compared to non-HIV infected patients in Japan
Dr. D. Ruzicka
MSD K.k., Japan
Prevalence of sarcopenia and associated risk factors among HIV-infected individuals receiving suppressive antiretroviral therapy
Dr. R. Rajasuriar
University of Malay, Malaysia
Social support plays a critical role in enhancing mental health among HIV-infected patients in Hanoi, Vietnam (not available)
Dr. M. Shoko
National Center for Global Health and Medicine, Japan
Parallel session 9: Innovative HIV testing, prevention and care service delivery models -
Recruiting people into HIV Services: eBooking
Panus Na Nakorn
Panus Na Nakorn
Thai Red Cross AIDS Research Centre, Thailand
Online platforms to spur HIV testing
Joseph Tucker, MD, PhD, AM
UNC Chapel Hill, United States
e-Cascade for real-time monitoring of HIV program
Matthew Avery
Matthew Avery
FHI 360 Bangkok, Thailand
Abstract presentations
Consideration regarding the service model on pre-exposure prophylaxis for men who have sex with men in the community
Dr. T.H. Kwan
Jockey Club School of Public Health and Primary Care, Hong Kong
Pre-exposure prophylaxis uptake among men who have sex with men at a clinic in Bangkok, Thailand, 2016
Dr. W. Wimonsate
Thailand Ministry of Public Health - U.S. CDC Collaboration, Thailand
Using a robust incentive-based, peer-centered model to identify new HIV cases among men who have sex with men, transgender women, and people who inject drugs in Cambodia
Dr. R. Sopha
Khmer HIV/AIDS NGO Alliance (KHANA), Cambodia
Plenairy session 3: Implementation of PrEP -
Population-based PrEP implementation in New South Wales, Australia
Andrew Grulich
Andrew Grulich
The Kirby Institute, University of New South Wales, Australia
Round Table Discussion: True demand from the communities
Midnight Poonkasetwattana
Midnigh Poonkasetwattana
Asia Pacific Coalition on Male Sexual Health, Thailand
Round Table Discussion: Genuine supply from the providers
Rossana Ditangco
Rossana Ditangco
Research Institute for Tropical Medicine, Philippines
PrEP research and implementation gaps
Michael Cassell
Michael Cassell
USAID, Thailand
Plenairy session 4: Access to hepatitis C treatment in the region -
Access to treatment/care on the global level
Access to treatment/care on the country level
Giten Khwairakpam
Giten Khwairakpam
TREAT Asia, Thailand
Barriers to access - Community perspective
Plenairy session 5: New drugs on the Horizon -
New HIV drugs / regimens
Daniel Kuritzkes, MD
Brigham and Women's Hospital / Harvard Medical School, United States
New hepatitis drugs
Jürgen Rockstroh, MD
University of Bonn, Germany
New TB drugs
Nicholas Paton, MD, FRCP
National University of Singapore, Singapore
Overview
Overview

The very successful 2nd Asia Pacific AIDS & Co-infections Conference (APACC) took place from 1 to 3 June 2017 in Hong Kong.

Organizing Committee would like to thank all invited speakers and participants for their contribution to this conference!

We would like to thank our supporters ViiV Healthcare, Gilead Sciences, AbbVie, Mylan and Hong Kong Toursim Board for making this event possible.

General Information 

Unique Features
- A program with a special focus on the needs in Asia and the Pacific

- A true scientific platform for regional clinicians and clinical researchers to present their data

- Insights into important clinical developments and updates on ongoing and new trials

- Capacity building workshops and career development sessions for young professionals

- A great opportunity to network with your colleagues throughout Asia
Who Should Attend?
- Medical professionals involved in the daily care of individuals infected with HIV and HIV-HCV, HIV-HBV, HIV-TB, and other HIV co-infections

- Clinical, translational, and basic researchers

- Clinicians, physicians, general practitioners, and nurses

- Residents, post-graduates, and PhD students

- Government agency personnel, NGO representatives, and health authority personnel

- Industry representatives

- Social workers, advocates, and community workers

- Other healthcare professionals involved in treating HIV and co-infected patients
Meeting Objectives
This meeting aims to:

- Promote dissemination and successful translation of new knowledge regarding HIV and co-infections while facilitating a neutral environment

- Foster new and lasting cross-disciplinary partnerships and collaborations between researchers in HIV, hepatitis, tuberculosis, policymakers, and NGOs, among others, in order to improve knowledge sharing, with the end goal of improving healthspan within the rapidly growing HIV/AIDS population

- Attract, showcase, and maintain new, early career, and underrepresented investigators to this multidisciplinary area of research and to translate novel findings into clinical practice
Learning Objectives
After participating in this activity, participants will be able to:

- Describe the major achievements and challenges in antiviral therapy for HIV and/or hepatitis-positive patients in the Asia Pacific region

- Identify improved treatment options for their patients

- Initiate (research) collaborations to further improve the level of knowledge on clinical management in the Asia Pacific region

- Use gained knowledge to make/advocate for appropriate adjustments to policies in public, institutional, and private settings

Practical Information 

Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this conference, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this conference. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official conference sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the conference is finished, provided the speaker has given permission to do so.
Committees
Program Committee
Organizing Committee
Scientific Committee

The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

  • Dashika Anshu Balak, MBBS
  • Zhiwei Chen, PhD, DVM
  • Jun Yong Choi, MD, PhD
  • Rino A Gani, MD, PhD (Indonesia)
  • Ishwar Gilada, MD, DDV, FCPS
  • Yee-Tak Hui, FHKAM, FRCPChien-Ching Hung, MD, PhD
  • Aikichi Iwamoto, MD, DMSci (Japan)
  • Thana Khawcharoenporn, MD, MSc
  • Saye Khoo, MD, PhD
  • N. Kumarasamy, MD, PhD
  • Eternity Labio, MD (Philippines)
  • Ching-Lung Lai, MD, FRCP, FRACP
  • Thuy Le, MD, DPhil
  • Christopher Lee, MBBS, MRCP, FRCP (Malaysia)
  • Man-Po Lee, MBBS, MSc, FHKCP, FHKAM, FRCP
  • Nelson Lee, MBBS, MD, FRCP, FHKCP, FHKAM (Hong Kong)
  • Seng Gee Lim, MBBS, FRACP, FRCP, MD
  • Hsi-Hsun Lin, MD, PhD
  • Hongzhou Lu, MD, PhD
  • Tuti Parwati Merati, MD, PhD (Indonesia)
  • Nguyen Lan Anh Thi, MD, PhD (Vietnam)
  • Nguyen Van Kinh, MD, PhD (Vietnam)
  • Shinichi Oka, MD, PhD
  • Praphan Phanuphak, MD, PhD
  • Kiat Ruxrungtham, MD
  • Joseph D. Tucker, MD, PhD
  • Yiming Shao, MD, PhD
  • Thomas Man-Kit So (Hong Kong)
  • Akifumi Takaori-Kondo, MD, PhD
  • Tawesak Tanwandee, MD (Thailand)
  • Owen Tsang, MBChB, MRCP, FHKCP, FHKAM, MTH, DTM&H, MSc, LSHTM, FRCP
  • Rudi Wisaksana, MD, PhD
  • Evy Yunihastuti, MD, PhD
  • Fujie Zhang, MD, PhD
  • Hui Zhuang, MD
Support
Titanium Level
Sliver Level
Support
Contributor
Language